Table 3.
QFT and TST results of patients excluding those lost to follow-up.
| HIV-uninfected children | HIV-infected children | Healthy adult donors | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Active TB categories | Total active TB | Respiratory diseases | p value | Active TB categories | Total active TB | Respiratory diseases | p value | ||||||
| Culture-confirmed | Highly probable | Probable | Culture-confirmed | Highly probable | Probable | ||||||||
| n | 7 | 7 | 5 | 19 | 60 | 0 | 10 | 3 | 13 | 18 | 33 | ||
|
| |||||||||||||
| QFT-IT (%) | 0.001 | 0.11 | |||||||||||
| Performed | 5 (71.4) | 7 (100.0) | 5 (100.0) | 17 (89.5) | 59 (98.3) | — | 9 (90.0) | 3 (100.0) | 12 (92.3) | 17 (94.4) | 32 (97.0) | ||
| Positive | 3 (60.0) | 4 (57.1) | 2 (40.0) | 9 (47.4) | 6 (10.2) | — | 1 (11.1) | 1 (33.3) | 2 (16.7) | 0 (0) | 13 (40.6) | ||
| Negative | 2 (40.0) | 2 (28.6) | 3 (60.0) | 7 (36.8) | 50 (84.7) | — | 8 (88.9) | 2 (66.7) | 10 (83.3) | 14 (82.4) | 19 (59.4) | ||
| Indeterminate | — | 1 (14.3) | — | 1 (5.3) | 3 (5.1) | — | — | — | — | 3 (17.6) | — | ||
| Not performed | 2 (28.6) | — | — | 2 (10.5) | 1 (1.7) | — | 1 (10.0) | — | 1 (7.7) | 1 (5.6) | 1 (3.0) | ||
|
| |||||||||||||
| TST test (%) | <0.0001 | 0.15 | |||||||||||
| Performed | 6 (85.7) | 7 (100.0) | 5 (100.0) | 18 (94.7) | 60 (100.0) | — | 10 (100.0) | 3 (100.0) | 13 (100.0) | 18 (100) | 0 | ||
| Positive | 3 (50.0) | 6 (85.7) | 2 (40.0) | 11 (57.9) | 10 (16.7) | — | 1 (10.0) | 2 (66.7) | 3 (23.1) | 1 (5.6) | — | ||
| Negative | 3 (50.0) | 1 (14.3) | 3 (60.0) | 7 (36.8) | 50 (83.3) | — | 9 (90.0) | 1 (33.3) | 10 (76.9) | 17 (94.4) | — | ||
| Not performed | 1 (14.3) | — | — | 1 (5.3) | — | — | — | — | — | 0 (0) | 33 (100.0) | ||
TB: tuberculosis; IQR: interquartile range; HIV: Human Immunodeficiency Virus; QFT-IT: QuantiFERON TB-Gold In-Tube; TST: tuberculin skin test.